Rohit Bhargava

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Use of immunohistochemistry in diagnosis of breast epithelial lesions
    Rohit Bhargava
    Department of Pathology, Magee Women Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Adv Anat Pathol 14:93-107. 2007
  2. pmc Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
    Molly E Klein
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI, USA
    Mod Pathol 26:658-64. 2013
  3. ncbi request reprint Low ER+ breast cancer: Is this a distinct group?
    Nika C Gloyeske
    Magee Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA 15213
    Am J Clin Pathol 141:697-701. 2014
  4. doi request reprint Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases
    Faye F Gao
    Magee Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA 15213
    Am J Clin Pathol 141:102-10. 2014
  5. doi request reprint Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 19:218-25. 2011
  6. doi request reprint Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA
    Cancer 116:1431-9. 2010
  7. doi request reprint Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 18:113-8. 2010
  8. doi request reprint Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 24:367-74. 2011
  9. doi request reprint Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma
    James A Kraus
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 20:334-9. 2012
  10. ncbi request reprint EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1027-33. 2005

Collaborators

Detail Information

Publications66

  1. ncbi request reprint Use of immunohistochemistry in diagnosis of breast epithelial lesions
    Rohit Bhargava
    Department of Pathology, Magee Women Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Adv Anat Pathol 14:93-107. 2007
    ..Because the main focus of this review is on diagnosis, receptor studies on breast carcinoma are briefly discussed and only a few general comments are made...
  2. pmc Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
    Molly E Klein
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI, USA
    Mod Pathol 26:658-64. 2013
    ..Conversely, an Oncotype DX result that is dramatically different from what is expected based on standard morphoimmunohistologic variables should be thoroughly investigated...
  3. ncbi request reprint Low ER+ breast cancer: Is this a distinct group?
    Nika C Gloyeske
    Magee Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA 15213
    Am J Clin Pathol 141:697-701. 2014
    ..Estrogen receptor (ER) level can be semiquantified by immunohistochemistry (IHC) using the H-score. The score, given as the sum of the percent staining multiplied by the intensity level, ranges from 0 to 300...
  4. doi request reprint Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases
    Faye F Gao
    Magee Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA 15213
    Am J Clin Pathol 141:102-10. 2014
    ....
  5. doi request reprint Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 19:218-25. 2011
    ..The consistent presence of IGF-1R in ER+ tumors may explain the lower response rate to neoadjuvant chemotherapy in luminal tumors...
  6. doi request reprint Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA
    Cancer 116:1431-9. 2010
    ..We hypothesize that a similar response could be predicted using semiquantitative immunohistochemistry for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2)...
  7. doi request reprint Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 18:113-8. 2010
    ..ERBB2 tumors demonstrate some features classically ascribed to TN basal-like tumors. Epidermal growth factor receptor overexpression in ERBB2 tumors may have additional predictive value...
  8. doi request reprint Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 24:367-74. 2011
    ..This information can be utilized to counsel patients considered for neoadjuvant chemotherapy and the same principle could be applied in the adjuvant setting...
  9. doi request reprint Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma
    James A Kraus
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 20:334-9. 2012
    ..E-cadherin expression as a predictor of pathologic complete response in triple-negative tumors should be further assessed on larger number of cases...
  10. ncbi request reprint EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1027-33. 2005
    ..Approximately 6% of breast carcinomas show EGFR amplification with EGFR protein overexpression and may be candidates for trials of EGFR-targeted antibodies or small inhibitory molecules...
  11. doi request reprint Histopathologic variables predict Oncotype DX recurrence score
    Melina B Flanagan
    Department of Pathology, Magee Women s Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 21:1255-61. 2008
    ..Although the Oncotype DX Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making...
  12. ncbi request reprint Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile
    David J Dabbs
    Department of Pathology, Magee Women s Hospital of UPMC, Pittsburgh, PA 15213, USA
    Mod Pathol 19:1506-11. 2006
    ....
  13. doi request reprint Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
    Leo A Niemeier
    Department of Pathology, Magee Women s Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Mod Pathol 23:205-12. 2010
    ..Androgen receptor-targeted therapy in estrogen/progesterone receptor-negative tumors may provide an inexpensive alternative to usual high-dose chemotherapy with or without trastuzumab...
  14. doi request reprint Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors
    Mirka W Jones
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Int J Gynecol Cancer 23:380-4. 2013
    ..When tumors are difficult to distinguish based on routine histologic sections, immunohistochemistry and human papillomavirus (HPV) in situ hybridization may be used...
  15. doi request reprint The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management
    Joan M Striebel
    Department of Pathology, Magee Womens Hospital, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 129:383-90. 2008
    ..These results support the recent American Society of Clinical Oncology/College of American Pathologists recommendations for further testing in cases with equivocal HER2 results...
  16. doi request reprint PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma
    Mamatha Chivukula
    Department of Pathology, Magee Women s Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA
    Int J Gynecol Pathol 28:570-8. 2009
    ..We therefore conclude that PAX 2 is a promising new, sensitive, and specific müllerian immunomarker for ovarian serous carcinomas (primary and metastatic)...
  17. doi request reprint Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors
    Siobhan M O'Connor
    Department of Pathology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Appl Immunohistochem Mol Morphol 18:268-72. 2010
    ..Given the additional advantages of hormone receptor IHC performed on intact tissue sections, currently there is no definitive reason to switch to RT-PCR for determination of ER and PR expressions...
  18. ncbi request reprint HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering, Cancer Center, New York, NY 10021, USA
    Am J Clin Pathol 123:889-95. 2005
    ..Identification of topo2a and HER-2 status might have therapeutic and prognostic implications...
  19. doi request reprint The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma
    Isil Z Yildiz-Aktas
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, PA 15213, USA
    Am J Clin Pathol 137:691-8. 2012
    ..ER, PR, and HER2 immunohistochemical results should be considered valid for cases fixed up to 96 hours...
  20. doi request reprint MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    Kandace P McGuire
    Department of Surgery, Magee Womens Hospital, University of Pittsburgh, 300 Halket St, Pittsburgh, PA, USA
    Ann Surg Oncol 18:3149-54. 2011
    ..We seek to quantify this MRI/pathology discrepancy and determine if the accuracy of MRI post NAC varies with tumor subtype...
  21. doi request reprint Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer
    John A Vargo
    Department of Radiation Oncology, Magee Womens Hospital of UPMC, University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA
    Oncology 80:341-9. 2011
    ..The molecular subtype by hormone receptor status predicts recurrence in the adjuvant setting. Here, we report recurrence patterns by molecular subtype following neoadjuvant chemotherapy (NACT) to identify subgroups prone to recurrence...
  22. pmc Biomarker profile in breast carcinomas presenting with bone metastasis
    Olga L Bohn
    Department of Pathology, Magee Women s Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213 3180, USA
    Int J Clin Exp Pathol 3:139-46. 2009
    ..The high morbidity associated to metastatic breast cancer prompts the identification of predictive biomarkers of relapse of breast tumors to categorize patients at high risk of bone metastasis and serve as targeted therapy...
  23. doi request reprint Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
    Xin Li
    Department of Pathology, Magee Womens Hospital of UPMC, Pittsburgh, PA
    Appl Immunohistochem Mol Morphol 21:420-5. 2013
    ..Semiquantitative scoring for hormone receptors provides useful information in terms of therapeutic response in HER2-positive tumors. ..
  24. pmc Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies
    Jing Yu
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Diagn Pathol 5:36. 2010
    ....
  25. doi request reprint Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases
    Nicole Nicosia Esposito
    Department of Pathology, Magee Womens Hospital of the University of Pittsburgh, Pittsburgh, PA, USA
    Am J Clin Pathol 131:228-42. 2009
    ..4 months). EPCs are in situ carcinomas with an excellent prognosis and can be managed with local therapy with or without sentinel lymph node biopsy...
  26. ncbi request reprint Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases
    Farbod Darvishian
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 28:1568-78. 2004
    ..We sought an immunohistochemical panel to minimize subjectivity in the distinction of USC from EEC...
  27. ncbi request reprint Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Pathol 123:237-43. 2005
    ..CISH performs as well as FISH in the analysis of HER-2 gene amplification in breast cancer and might have advantages in certain situations...
  28. ncbi request reprint Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin
    David J Dabbs
    Department of Pathology, Magee Women s Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Am J Surg Pathol 31:427-37. 2007
    ..Caution should be exercised when examining tumors in metastatic sites with P120ctn, with the incorporation of an appropriate panel of immunostains...
  29. doi request reprint Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases
    Mamatha Chivukula
    Department of Pathology, Magee Women s Hospital of UPMC, Pittsburgh, PA 115213, USA
    Mod Pathol 21:363-8. 2008
    ..However, performing fluorescence in situ hybridization on core-needle biopsies almost completely resolves the issue of heterogeneous expression of HER2...
  30. doi request reprint NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin
    Anna H Woodard
    Dept of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, PA 15213, USA
    Am J Clin Pathol 136:428-35. 2011
    ..Addition of NY-BR-1 and PAX8 in a panel would be useful in distinguishing breast cancer, gynecologic tumors, and tumors of the upper gastrointestinal tract...
  31. pmc Nuclear nano-morphology markers of histologically normal cells detect the "field effect" of breast cancer
    Rajan K Bista
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Breast Cancer Res Treat 135:115-24. 2012
    ....
  32. doi request reprint Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study
    James A Kraus
    Department of Pathology, Pittsburgh, PA, USA
    Mod Pathol 25:869-76. 2012
    ....
  33. doi request reprint Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium
    Kazuya Onuma
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Int J Gynecol Pathol 27:418-25. 2008
    ..MGB may be a promising new adjunctive marker in gynecologic pathology...
  34. doi request reprint CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 130:724-30. 2008
    ..Both antibodies had comparable specificity of more than 95%. For positive cases, the percentage and intensity of staining was much higher with CK5 than with CK5/6 (P = .0001)...
  35. doi request reprint Clinicopathologic implications of "flat epithelial atypia" in core needle biopsy specimens of the breast
    Mamatha Chivukula
    Dept of Pathology, Magee Women s Hospital of UPMC, University of Pittsburgh, PA 15213, USA
    Am J Clin Pathol 131:802-8. 2009
    ..Our study concludes that there is an association of FEA with ADH on multiple levels of CNB specimens, and follow-up surgical excision findings for FEA are clinically significant...
  36. doi request reprint Basal-like subtype breast cancers in women older than 40 years of age
    Cagatay Ersahin
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Int J Surg Pathol 18:42-7. 2010
    ..BL cancer patients from all age groups require further investigation for BRCA-1, as well as gene microarray analysis to compare the gene expressions with those observed in the younger population...
  37. doi request reprint Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics
    Jing Yu
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 136:88-97. 2011
    ..ER is still expressed in HER2+ classical ILCs, although the level of expression is significantly reduced compared with the HER2- cases. The implications of the findings are discussed...
  38. doi request reprint High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study
    David J Dabbs
    Magee Womens Hospital of UPMC, 300 Halket St, Pittsburgh, PA, USA
    J Clin Oncol 29:4279-85. 2011
    ..Because of the lack of independent evaluation, this quality assurance study was undertaken to define the concordance rate between immunohistochemistry (IHC)/fluorescent in situ hybridization (FISH) and GHI RT-PCR HER2 assay...
  39. ncbi request reprint Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1857-62. 2006
    ..Two antibodies, the PharmDx kit and the 31G7 clone, are used commonly for immunohistochemistry by various laboratories. No comparative studies on the performance of these 2 antibodies are available...
  40. doi request reprint A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast
    Jing Yu
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Hum Pathol 44:394-401. 2013
    ..However, several technical and logistic issues await significant improvement before this novel technique can be justified for routine clinical application...
  41. doi request reprint Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma
    David A Cohen
    Department of Pathology, Magee Womens Hospital of UPMC, Pittsburgh, PA, USA
    Am J Clin Pathol 138:796-802. 2012
    ..85 (95% confidence interval [CI] = 0.79-0.90) for ER and 0.87 (95% CI = 0.82-0.92) for PR. Because the H-score provides a continuous measure of tumor hormone receptor content, we suggest universal adoption of this method...
  42. doi request reprint The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma
    Isil Z Yildiz-Aktas
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 25:1098-105. 2012
    ..The ASCO/CAP guideline of cold ischemic time period of <1 h is a prudent guideline to follow...
  43. doi request reprint Localization of CD44 and CD90 positive cells to the invasive front of breast tumors
    Vera S Donnenberg
    University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, USA
    Cytometry B Clin Cytom 78:287-301. 2010
    ..A variety of markers have been proposed to identify breast cancer stem cells. Here, we used immunohistostaining and flow cytometry to analyze their interrelationships and to sort cells for tumorigenicity studies...
  44. ncbi request reprint Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Diagn Mol Pathol 13:213-6. 2004
    ..The overall concordance for HER-2 status by IHC between whole sections and TMA cores was 86% (94 out of 109 cases). TMAs are a reliable approach to study HER-2 gene amplification in a high throughput manner...
  45. doi request reprint Thyroid transcription factor-1 and "basal marker"--expressing small cell carcinoma of the breast
    Cagatay Ersahin
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois, USA
    Int J Surg Pathol 17:368-72. 2009
    ..An unequivocal in situ component was identified intimately admixed with the invasive carcinoma. To the authors' knowledge, this is the first report of breast small cell carcinoma showing the expression of "basal markers."..
  46. doi request reprint WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes
    Akosua B Domfeh
    Department of Pathology, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Mod Pathol 21:1217-23. 2008
    ..The degree of WT1 expression was generally weak to moderate (>90% cases) and rarely strong (<10% cases). None of the breast carcinoma subtype unassociated with mucinous component showed WT1 expression...
  47. doi request reprint Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases
    Beth Z Clark
    Department of Pathology, Magee Womens Hospital of UPMC, Pittsburgh, PA 15213, USA
    Appl Immunohistochem Mol Morphol 21:287-91. 2013
    ....
  48. doi request reprint Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?
    Faye F Gao
    Department of Pathology, Magee Women s Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213 3180, USA
    Hum Pathol 44:1534-43. 2013
    ..These findings support the hypothesis that STIC acts as a precursor lesion for most fallopian tube, ovarian, and peritoneal HGSCs, but not for endometrial HGSC. ..
  49. doi request reprint Uterine adenosarcomas: diagnostic use of the proliferation marker Ki-67 as an adjunct to morphologic diagnosis
    Nidhi Aggarwal
    University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Int J Gynecol Pathol 31:447-52. 2012
    ..Thus, characteristic zonation by Ki-67-staining pattern is a helpful adjunct to the routine morphology in the diagnosis of AS, particularly in curettage specimens, which may lack some of the classic morphologic diagnostic features...
  50. doi request reprint Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report
    Dana Gingell
    Department of Pathology, Magee Women s Hospital of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Int J Gynecol Pathol 29:243-7. 2010
    ..Morphologic and immunohistochemical examination of the specimens helped to clarify the correct diagnosis of primary ovarian carcinoma with widespread metastases to bilateral breasts...
  51. ncbi request reprint Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 127:103-13. 2007
    ..Positive mammaglobin staining was also seen in 44 (8.1%) of 544 nonbreast tumors. Mammaglobin is a more sensitive marker than GCDFP-15 for breast carcinoma; however, it lacks the specificity of GCDFP-15...
  52. ncbi request reprint Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma
    Lorenzo Pasquali
    Division of Immunogenetics, Department of Pediatrics Rangos Research Center, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Lett 257:136-44. 2007
    ..Methylation increased from normal to hyperplasia, the increase being significantly higher in invasive and in situ tumors for RASSF1A (p=0.00006 and p=0.009, respectively)...
  53. pmc Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions
    Lu Wang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Mol Diagn 9:498-509. 2007
    ..As these data further support, these types of EWS fusions are associated with primitive extraskeletal small round cell sarcomas of uncertain lineage arising mainly in the pediatric population...
  54. doi request reprint Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues
    Nicholas W Bateman
    Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Proteome Res 10:1323-32. 2011
    ....
  55. pmc Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers
    Rohit Bhargava
    Department of Pathology, Magee Womens Hospital of University of Pittsburgh Medical Center Pittsburgh, PA, USA
    Int J Clin Exp Pathol 2:444-55. 2009
    ..Immunohistochemistry is a reliable surrogate tool to classify breast carcinoma according to the gene expression profile classification...
  56. pmc A quantitative reverse transcription-PCR assay for rapid, automated analysis of breast cancer sentinel lymph nodes
    Steven J Hughes
    Departments of Surgery, University of Pittsburgh, 497 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, USA
    J Mol Diagn 11:576-82. 2009
    ..Furthermore, the assay is not dependent on subjective interpretation, is reproducible across three clinical environments, and is rapid enough to allow intraoperative decision making...
  57. ncbi request reprint Intraductal location of the sclerosing adenosis of the breast
    Bulent Unal
    Department of Surgical Oncology, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Bratisl Lek Listy 110:251-2. 2009
    ..Ductoscopy and development of ductoscopy guided biopsy techniques may be used as an early diagnostic method for the ductal breast lesions (Fig. 2, Ref. 10). Full Text (Free, PDF) www.bmj.sk...
  58. pmc Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model
    Eun Ryeong Hahm
    Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Natl Cancer Inst 105:1111-22. 2013
    ..Efficacy of withaferin A (WA), an Ayurvedic medicine constituent, for prevention of mammary cancer and its associated mechanisms were investigated using mouse mammary tumor virus-neu (MMTV-neu) transgenic model...
  59. ncbi request reprint Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:40-7. 2005
    ..We therefore recommend the use of a small antibody panel comprising anti-CD10, anti-estrogen receptor, and anti-CD34 to distinguish endometrial stromal sarcomas from tumors with a predominant hemangiopericytomatous growth pattern...
  60. doi request reprint Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues
    Stergios J Moschos
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Hum Pathol 41:1286-98. 2010
    ....
  61. doi request reprint Mucosa-associated lymphoid tissue lymphoma of the cervix
    Devin Coon
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 26:503-4. 2008
  62. pmc Spatial-domain low-coherence quantitative phase microscopy for cancer diagnosis
    Pin Wang
    Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Opt Lett 35:2840-2. 2010
    ..Because this technique is sensitive and does not require special sample processing, it can be disseminated to all clinical settings...
  63. ncbi request reprint Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method
    Rohit Bhargava
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Diagn Mol Pathol 14:72-6. 2005
    ..We conclude that CISH is an accurate method for determining MYCN gene amplification, with added advantages that make it a more practically useful method...
  64. ncbi request reprint Infrared spectroscopic imaging for histopathologic recognition
    Daniel C Fernandez
    Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 0520, USA
    Nat Biotechnol 23:469-74. 2005
    ..Finally, we differentiate benign from malignant prostatic epithelium by spectroscopic analyses...